Vyvanse Medicare Part D Coverage: What to Expect in 2026

Does Medicare Part D Cover Vyvanse?

Medicare Part D plans are legally permitted to cover Schedule II controlled substances, and most formularies include lisdexamfetamine in some form. Brand-name Vyvanse typically lands on Tier 3 or Tier 4 of a Part D formulary, while generic lisdexamfetamine capsules generally sit at Tier 1 or Tier 2. That tier difference can cut your monthly cost-share from over $100 to under $15 in many plans.

Coverage is not automatic. You should use the Medicare Plan Finder tool at medicare.gov or call 1-800-MEDICARE to confirm your specific plan's formulary before your prescription is written. Formularies change on January 1 of each plan year, so even if your plan covered lisdexamfetamine last year, re-verification is necessary.

Why Schedule II Status Matters for Part D

The Controlled Substances Act classifies lisdexamfetamine as Schedule II, the same category as oxycodone and methylphenidate. Federal law does allow Part D plans to include Schedule II drugs, but plans may impose additional utilization management tools, such as quantity limits, step-therapy requirements, or prior authorization, beyond what they apply to non-controlled medications. CMS guidelines confirm that Part D sponsors may cover Schedule II controlled substances but are not required to do so for every formulary.

The 2025-2026 Out-of-Pocket Cap and How It Helps

Starting in 2025, the Inflation Reduction Act capped annual out-of-pocket spending for Part D enrollees at $2,000. For patients who rely on brand-name Vyvanse because a generic does not meet their clinical needs, this cap is meaningful. Once you reach $2,000 in true out-of-pocket spending across all Part D drugs in a calendar year, your cost-share drops to $0 for the rest of the year. The CMS summary of the Inflation Reduction Act Part D redesign explains the full structure.

Generic Lisdexamfetamine: The Single Biggest Cost Lever

Generic lisdexamfetamine capsules entered the U.S. Market in August 2023 after Takeda's exclusivity period ended. The FDA's Orange Book lists multiple approved manufacturers. For most Medicare beneficiaries, switching from brand Vyvanse to a generic lisdexamfetamine product is the most direct path to lower cost-sharing.

What the FDA Says About Bioequivalence

The FDA requires generic manufacturers to demonstrate bioequivalence to the reference listed drug, meaning the generic must deliver the same active moiety (d-amphetamine, released after first-pass metabolism of lisdexamfetamine) at the same rate and extent. The FDA's bioequivalence guidance defines acceptable parameters as 80-125% confidence intervals for Cmax and AUC. For most patients with ADHD or binge eating disorder, generic lisdexamfetamine performs identically to brand Vyvanse in practice.

A small proportion of patients report subjective differences between brand and generic stimulants. If you or your prescriber believe a brand-name-only medical necessity exists, your plan may allow a formulary exception request, discussed below.

Typical Generic Prices in 2026

• GoodRx/cash price (generic, 30 capsules): approximately $30-$40 depending on pharmacy and dose
• Part D Tier 1 cost-share with generic: often $0-$10 with most standard plans
• Part D Tier 3 cost-share with brand: often $40-$120 depending on plan design

Prices shift by pharmacy, dose strength, and plan. Always run a real-time pharmacy check on your plan's drug pricing tool or at GoodRx.com before filling.

Prior Authorization: How to Manage It

Most Part D plans require prior authorization (PA) before they will cover lisdexamfetamine at all, brand or generic. PA requirements exist because stimulants are Schedule II and because plans want to confirm an ADHD or binge eating disorder diagnosis has been formally established.

What Documentation Your Prescriber Will Need

A standard PA for lisdexamfetamine typically requires:

• A confirmed diagnosis of ADHD (ICD-10: F90.x) or binge eating disorder (F50.81)
• Documentation that the prescriber is licensed to prescribe Schedule II controlled substances in your state
• Patient age confirmation (lisdexamfetamine is FDA-approved for ADHD in patients aged 6 and older, and for binge eating disorder in adults)
• In some plans, evidence of a previous trial of a cheaper stimulant such as mixed amphetamine salts (Adderall generics) or methylphenidate

The American Psychiatric Association's practice guideline for ADHD notes that stimulant medications remain the first-line pharmacologic treatment for ADHD across the lifespan. The full guideline is available through the APA. Having that guideline language available helps prescribers write stronger PA letters.

What to Do If Your PA Is Denied

A denial is not final. You have three formal options:

1. Formulary exception request. Ask your plan to cover the drug at a lower tier or waive the PA requirement based on medical necessity documentation from your prescriber.
2. Coverage determination appeal. File a formal appeal within 60 days of the denial notice. Your plan must respond within 72 hours for standard requests or 24 hours for expedited requests.
3. Step-therapy exception. If the plan requires you to try a different stimulant first and your prescriber believes that step is medically inappropriate, they can document a step-therapy exception. CMS regulations on step-therapy exceptions are codified at 42 CFR 423.

Keep written records of every phone call, denial letter, and submission date. These records are required if you escalate to the Medicare Appeals Council or a federal district court.

Extra Help (Low Income Subsidy): Coverage for Lower-Income Beneficiaries

Medicare's Extra Help program, officially the Low Income Subsidy (LIS), covers most or all Part D premiums and cost-sharing for qualifying beneficiaries. In 2026, the income threshold for full Extra Help is approximately 135% of the federal poverty level, with partial subsidy available up to 150%.

With full Extra Help, your cost-share for a generic Tier 1 or Tier 2 drug such as generic lisdexamfetamine is typically $0 to $4.50 per fill. Brand-name drugs with full Extra Help cost no more than $12.15 per fill in 2026.

Apply for Extra Help directly at the Social Security Administration website or call 1-800-772-1213. Many people who qualify for Extra Help are not enrolled. If your income is near the threshold, applying takes about 15 minutes online.

Manufacturer Savings Programs: What Medicare Beneficiaries Can and Cannot Use

Takeda offers a Vyvanse savings card program for commercially insured patients. Medicare beneficiaries are explicitly excluded from using manufacturer coupons or copay cards under federal anti-kickback regulations. Using a manufacturer coupon when you have Medicare Part D is a federal compliance violation that could expose you to liability.

This is a common source of confusion at the pharmacy counter. If a pharmacist offers you a coupon or savings card for Vyvanse, confirm whether you are using your Medicare Part D benefit. If you are, decline the coupon.

The HealthRX clinical team uses the following decision framework for Medicare patients asking about Vyvanse cost:

Step 1. Confirm generic lisdexamfetamine is on your plan's formulary. If yes, request generic at the pharmacy. Step 2. If generic is not covered or is subject to PA, have your prescriber submit the PA with diagnosis codes and clinical notes. Step 3. If PA is denied, request a formulary exception based on medical necessity. Step 4. If you meet income criteria, apply for Extra Help before the next plan year. Step 5. If total annual cost still exceeds the $2,000 IRA cap, track your True Out-of-Pocket (TrOOP) spending and notify your pharmacy to apply the cap when reached. Step 6. For patients paying cash while resolving coverage disputes, generic lisdexamfetamine at a warehouse club pharmacy (Costco, Sam's Club) or using a free discount card from NeedyMeds.org can reduce the cost to approximately $30-$40 per month.

Comparing Part D Plan Options During Open Enrollment

Medicare Open Enrollment runs October 15 through December 7 each year, with coverage effective January 1. If your current plan does not cover lisdexamfetamine or places it on an expensive tier, switching plans during Open Enrollment is your best long-term solution.

How to Use the Medicare Plan Finder

The Medicare Plan Finder at medicare.gov allows you to enter your specific drugs and dosages, then compare total estimated annual costs (premiums plus cost-sharing) across all plans available in your ZIP code. For a patient taking lisdexamfetamine 50 mg once daily, the Plan Finder will show you exactly which plans cover it, at what tier, and what your estimated annual cost-share will be.

Run this comparison every October. Plan formularies change annually, and a plan that was optimal in 2025 may not be optimal in 2026.

Medicare Advantage vs. Standalone Part D

If you have a Medicare Advantage (Part C) plan with built-in drug coverage, your lisdexamfetamine coverage comes through that plan's drug benefit rather than a standalone Part D plan. The same formulary, PA, and tier rules apply. Use the Plan Finder to compare Advantage plans as well as standalone Part D plans.

Medicare Supplement (Medigap) plans do NOT include drug coverage. Medigap enrollees must purchase a separate Part D plan for prescription coverage.

Medicaid and Dual-Eligible Beneficiaries

Patients enrolled in both Medicare and Medicaid (dual-eligible) receive prescription drug coverage through Medicare Part D rather than Medicaid for most drugs. However, dual-eligible beneficiaries automatically qualify for full Extra Help, meaning their lisdexamfetamine cost-share will be at the low Extra Help rates described above.

CMS guidance on dual-eligible special needs plans (D-SNPs) provides additional detail.

Binge Eating Disorder Diagnosis and Part D Coverage

Lisdexamfetamine holds two FDA approvals: ADHD (ages 6 and up) and moderate-to-severe binge eating disorder (adults). Part D covers both indications. Some plans, though, specifically flag binge eating disorder prescriptions for additional scrutiny because the diagnosis is newer and less commonly associated with stimulant prescribing.

If your prescription is for binge eating disorder, your prescriber's PA documentation should reference the FDA approval from 2015 and include the DSM-5 diagnostic criteria your patient meets. The original FDA approval for Vyvanse in BED is documented in the FDA drug label. Having the label language in the PA letter strengthens the case significantly.

A 2015 study in the Journal of Clinical Psychiatry (N=724) found that lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week versus placebo (P<0.001), providing the clinical backbone for the BED indication. That trial is indexed on PubMed.

Quantity Limits and How They Interact With Your Prescription

Many Part D plans impose quantity limits (QL) on Schedule II stimulants. A common limit is a 30-day supply dispensed at a time, regardless of how many days your prescription covers. This is consistent with most state laws governing Schedule II prescriptions.

Some plans also apply a monthly quantity cap at a specific number of capsules per 30 days. If your prescriber writes for a dose-titration schedule (for example, 30 mg for two weeks then 50 mg for two weeks), confirm that the combined quantity does not trigger a plan-level quantity limit rejection.

A pharmacist can run a real-time adjudication test before you arrive to pick up the prescription, which saves everyone time.

State Pharmaceutical Assistance Programs (SPAPs)

Several states operate State Pharmaceutical Assistance Programs that coordinate with Part D to further reduce cost-sharing. States with active SPAPs as of 2026 include New Jersey (PAAD), Pennsylvania (PACE), and New York (EPIC), among others. Eligibility and covered drugs vary by state. NCSL maintains a state-by-state SPAP directory.

If you live in a state with an SPAP, enrolling may reduce your lisdexamfetamine cost-share below even the Extra Help level.

Clinical Context: Why Lisdexamfetamine Persists in Treatment Plans

Lisdexamfetamine is a prodrug. It is pharmacologically inactive until enzymatic cleavage in the gastrointestinal tract releases d-amphetamine. This mechanism produces a smoother onset and longer duration of action compared to immediate-release amphetamine salts and reduces the abuse-diversion potential relative to direct-release amphetamines, according to the prescribing information.

The FDA-approved dosage range is 20 mg to 70 mg once daily. Titration typically begins at 30 mg and increases in 10 mg or 20 mg increments at weekly intervals.

A 2013 meta-analysis published in PLOS ONE (N=2,496 across included trials) found that lisdexamfetamine produced statistically significant improvements in ADHD symptom scores compared to placebo across age groups, with an effect size comparable to other long-acting stimulants. That meta-analysis is accessible on PubMed.

The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameter states: "Stimulant medications are safe and effective treatments for ADHD and should be considered as part of a comprehensive treatment plan." The full practice parameter is published in the Journal of the American Academy of Child and Adolescent Psychiatry.

What to Tell Your Doctor Before Open Enrollment

Before October 15 each year, schedule a brief check-in with your prescriber specifically about your Medicare drug coverage. Bring:

• Your current plan's formulary document (available on your plan's website)
• A printed or digital cost estimate from Medicare Plan Finder for the coming year
• A list of all your current prescriptions, not just lisdexamfetamine

If the plan estimate shows high out-of-pocket costs, your prescriber may be able to submit a PA earlier in the process, or may discuss whether the generic adequately meets your clinical needs. Changing plans during Open Enrollment, rather than waiting and fighting a PA mid-year, saves months of pharmacy-counter friction.